177Lu-PSMA-3-RGD

177Lu-PSMA-3-RGD: sourced facts only. name: "To address this, we developed a novel dual-targeting radioligand, 177Lu-PSMA-3-RGD, via solid-phase synthesis and click chemistry, designed to simultaneously bind prostate-specific membrane antigen (PSMA) and integrin αvβ3." [PMID:42503815]; target: "To address this, we developed a novel dual-targeting radioligand, 177Lu-PSMA-3-RGD, via solid-phase synthesis and click chemistry, designed to simultaneously bind prostate-specific membrane antigen (PSMA) and integrin αvβ3." [PMID:42503815]; developer: "State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou215123, China." [PMID:42503815]; modality: "To address this, we developed a novel dual-targeting radioligand, 177Lu-PSMA-3-RGD, via solid-phase synthesis and click chemistry, designed to simultaneously bind prostate-specific membrane antigen (PSMA) and integrin αvβ3." [PMID:42503815]; stage: "Furthermore, therapeutic administration of 177Lu-PSMA-3-RGD resulted in significantly greater tumor growth delay compared to single-targeted radioligands, without inducing observable systemic toxicity." [PMID:42503815]